Stereotactic prostate focal reirradiation therapy for local recurrence: preliminary results of Hartmann Oncology Radiotherapy Group

1,2NATHANIEL SCHER, MD, 1,2OLIVIER BAUDUCEAU, MD, 1,2MARC BOLLET, MD, 1,2HANAH LAMALLEM, MD,
3TOMER CHARAS, MD, 1PASCAL GARAUD, PhD, 1DENIS FOSTER, MD, 1MAHER FAWZI, PhD, 1MONA LABIDI, MD and
1,2ALAIN TOLEDAO, MD

1Hartmann Radiotherapy Institute, Hartmann Oncology Radiotherapy Group, Levallois-Perret, France
2Rafael Institute Center for Predictive Medicine, Levallois-Perret, France
3Department of Radiation Oncology, MSKCC, New York, USA

Address correspondence to: Dr Nathaniel Scher
E-mail: nathaniel.scher@gmail.com

Objective: Our objective was to report our experience and to evaluate the feasibility and toxicity of focal salvage stereotactic body radiation therapy (SBRT) in patients with post-radiation local recurrence of prostate cancer.

Methods: We retrospectively reviewed medical records of patients treated with Cyberknife® between October 2014 and April 2017 at our institution for a focal reirradiation delivered to the prostate/prostatic bed for local recurrence after radical or adjuvant radiotherapy. All patients underwent prostate biopsies at recurrence at the time of fiducial markers placement, had choline PET/CT and pelvic MRI. The treatment consisted in 36 Gy in six fractions delivered every other day. Post reirradiation toxicities were assessed according to the CTCAE v4 (Common Terminology Criteria for Adverse Events).

Results: 42 patients were treated with followed with a median follow-up of 21 months (range 3 – 31). 34 patients had biopsy proven recurrence. The initial treatment was radical prostatectomy and radiation therapy for 9 patients and radiation therapy alone for 33 patients. 23 patients from the group of prostate reirradiation had placement of rectal spacers. No Grade 4 or 5 toxicity were observed. 27 acute urinary events were recorded: 18 patients experienced Grade 1, 9 patients experienced Grade 2 toxicity and 1 patient experienced Grade 3 urinary toxicity, namely cystitis and/or dysuria. No Grade 2 or more digestive toxicity was observed. Rectal doses were significantly lower with rectal spacers.

Conclusion: Salvage focal Cyberknife® seems feasible and show promising results.

Advances in knowledge: SBRT for local prostate cancer recurrence after initial radiotherapy is well tolerated with short follow-up.
and salvage cryotherapy is somewhat limited due to treatment-related toxicity.

Studies of external beam reirradiation have been published for various tumor sites but they have scarcely been reported for intra prostatic recurrence. Indeed, several reasons could explain the rarity of this treatment: risk for normal tissue complication after high radiation dose, frequent metastatic evolution and elderly age. The technical evolution of radiotherapy offers new opportunities to treat small target with high radiation dose. SBRT has dosimetric and radiobiologic advantages as a salvage treatment paradigm. To limit normal tissue toxicity in the reirradiation situation, the target volume is confined to the recurrent macroscopic tumor in most clinical situations without targeting larger areas of potential microscopic spread.

CyberKnife® (Accuray, Sunnyvale, CA) was established in our institution in 2014 and has been used to treat prostate cancer local relapses that are not eligible for other treatment modalities. The aim of this study was to retrospectively report our clinical experience and evaluate the safety, feasibility and toxicity of salvage stereotactic body radiation therapy (SBRT) using CyberKnife® in patients with post-radiation local recurrence of prostate cancer.

METHODS

Patient selection

We retrospectively reviewed medical records of patients treated with salvage CyberKnife® for a post-radiation prostate cancer local recurrence between October 2014 and April 2017 at Hartmann Radiotherapy Institute. We collected clinical, biological parameters and dosimetric data. Patient reported outcomes and toxicities of the treatment were also collected according CTCAE v4 for all patients. Primary radiation therapy followed guidelines for low risk prostate cancer without ADT, for intermediate risk prostate cancer with short term ADT, for localized high-risk prostate cancer with long term ADT and for postoperative external-beam radiation therapy after radical prostatectomy. Inclusion criteria for reirradiation were: (1) The presence of a single recurrence from prostate cancer; (2) Exclusion of any metastases (choline PET/CT); (3) Diagnosis of prostate recurrence was based on biochemical failure confirmed by imaging studies; (4) Interval between first diagnosis of prostate cancer and diagnosis of recurrent disease of was greater than ≥ 2 years; (5) No severe (CTCAE v4 grade ≥3) chronic late toxicity; (6) Provision of written informed consent about this experimental treatment; (7) Presentation of case to multidisciplinary uro-oncology clinic. At time of recurrence, all patients underwent prostate biopsies and fiducial markers placement. All patients from the group prostate reirradiation underwent rectal spacer placement if they were treated after July 2015 (start date of the spacer implantation technique and a total of 42 patients were reviewed. Exclusion criteria were patients with lymph nodes metastasis and/or distant metastasis at time of reirradiation and those who underwent another local salvage local therapy. Table 1 shows patient characteristics. This study was approved by our Institutional Committee on Human Research.

Planning and treatment (Tables 1 and 2)

Stereotactic reirradiation was delivered using the CyberKnife® accelerator (Accuray, Sunnyvale, CA). For all patients, four gold fiducial markers were placed in the prostate or in the prostate bed via trans-rectal ultra-sonography for tracking modalities. Then, a non-contrast pelvic CT scan with 1.25-millimeter slice...
thickness were performed. The Gross Tumor Volume (GTV) was defined as the recurrence observed on multiparametric MRI and the delineation was guided by PET/CT images. GTV based on MRI T2 was delineated by a radiation oncologist. If the T2 image showed hypo intensity and PET/CT image also indicated a lesion at the same location, the region was considered positive. The presence of tumor recurrence on PET/CT images was defined as any monofocal uptake greater than adjacent background uptake in more than one slice within the CT defined prostate gland. To exclude background signalling, the bladder was delineated and excluded from GTV PET if necessary. Clinical Target Volume (CTV) was defined as GTV for prostate recurrence and GTV plus 1 mm margin for prostate bed recurrence. The Planning Target Volume (PTV) was defined as the CTV plus a 3 mm margin for prostate recurrence and CTV plus 1 mm margin for prostate bed recurrence. The following organs at risk were delineated on each slice: rectum, bladder, femoral heads, penile bulb, bowel, testicles. The stereotactic radiation therapy dose prescribed was 36 Gy on the 80% isodose line, in six fractions, three fractions a week. Normal tissue dose constraints for planning are for the rectum: V27 <20 cm3 and D max = 40.5 Gy ; and for the bladder V19 <15cm3 V40<5 cm3. Cyberknife® imaging system was taking X-ray images each 45 sec in order to provide real-time information about the location of the prostate/prostate bed and enable the system to dynamically track and correct for any movement of the target. All four fiducials selected at the planning stage were actually tracked during each treatment session fraction. Table 2 shows treatment characteristics.

Table 2. Treatment characteristics (n = 42)

| Number of patients | Prostate (n = 33) | Prostate bed (n = 9) | Total (n = 42) |
|--------------------|------------------|---------------------|---------------|
| Pre reirradiation PSA |                  |                     |               |
| Median [range] (months) | 3.3 [0.05;23.7] | 1.1 [0.01;3.1] | 3.1 [0.01;23.7] |
| ADT group | 0.4 [0.05–1.1] | 0.3 [0.01–0.07] | 0.3 [0.01–1.1] |
| Non-ADT group | 4 [2.5–23.7] | 2.6 [2.2–3.1] | 3.9 [2.2–23.7] |
| ADT added to reirradiation | 5 | 3 | 8 (19%) |
| Median duration of ADT (months) | 6 | 6.1 | 6 |
| Median time from start of ADT to re irradiation (months) | 3 [1-10] | 3 [1-5] | 3 [1-10] |
| Recurrence biopsy proven | 28 | 6 | 34 (80%) |
| Pelvic MRI before reirradiation | 33 (78%) | 9 (22%) | 42 (100%) |
| Rectal spacers | 23 | 0 | 23 (55%) |
| CyberKnife® data | | | |
| Median total dose (Gy) | 36 | 36 | 36 |
| Dose/fraction | 6 | 6 | 6 |
| Number of fractions | 6 | 6 | 6 |
| Estimated duration of a fraction (mn) | 30.7 | 28.8 | 30.3 |

Dosimetric data
We retrospectively collected the dosimetric data for all patient for PTV, CTV and organs at risk (bladder and rectum) using Multiplan. Table 3 shows the dosimetry of 42 patients. We also evaluated the effect of the hydrogel rectal spacer on rectal dosimetry and the thickness of the rectal spacer at midgland.

Follow up after salvage reirradiation:
After salvage reirradiation, each patient was seen at 6 weeks, 3 months and then every 6 months by a radiation oncologist to assess clinical toxicities and PSA level. The severities of acute (within 30 days of ending radiation) and late toxicities were evaluated according to the Common Terminology Criteria for Adverse Events (CTCAE) version 4.0. In this study, biochemical response to treatment was classified as a reduction, stabilization, or progression in the level of PSA. A substantial reduction in PSA level (>50% PSA of initial value) was considered as a complete biochemical response; a reduction between 10 and 50% of the initial value was considered as a partial response and if it oscillated within the 10% margins of the initial value, it was classified as a stabilization; an increase of more than 10% was considered as a progression. The initial PSA value was the last value measured before the reirradiation. The group of patients treated with neoadjuvant, concomitant or adjuvant ADT was excluded for the evaluation of biochemical response. All patients with biochemical failure underwent a choline PET/CT. Biochemical failure was defined according the Phoenix ASTRO criteria as a rise of PSA of at least 2 ng ml−1 above the nadir after EBRT.14 Clinical progression was classified as the development of the disease in field or out field or distant metastasis.

Statistical method
The statistical comparisons were performed using Mann-Whitney test with estimation of the p value by Monte-Carlo method (1,0000 iterations). p values were two-sided and
considered to be statistically significant if less than 0.05. Calculations were made with the use of Addinsoft © XLSTAT (2016 - Premium).

RESULTS PATIENTS
Between October 2014 and April 2017, 42 patients with an isolated recurrence of prostate cancer were included with a median follow up of 21 months (range 3–31) (Table 4). For the primary treatment, radical prostatectomy and radiation therapy was performed in nine patients and radiation therapy alone in 33 patients. The initial disease category according to D’Amico group was low for six patients, intermediate for 15 patients and high for 21 patients. The interval between the diagnosis of prostate cancer and the first day of CyberKnife® treatment ranged from 29 to 204 months (median, 82 months). All patient had prostate biopsies at recurrence. 34 patients have pathological features of malignancy: 28 from the prostate group and eight from the prostate bed group. At time of diagnosis of local recurrence, all patients underwent a choline PET/CT and a multi parametric prostate MRI. In addition, 21 patients (50%) underwent a multi parametric prostate MRI the week before simulation CT and for them, MRI and CT images were registered with image fusion. eight patients have received a neoadjuvant and concomitant ADT associated with salvage therapy for a mean duration of 6 months. The median time from start of ADT to reirradiation was 3 months (range, 1 to 10). The median PSA level at the time of salvage therapy for patient who have received ADT were 0.4 [0.05–1.1] for prostate group and 0.3 [0.01–0.07] for prostate bed group. The median PSA level at time of salvage therapy for patient who have not received ADT were 4 [2.5–23.7] for prostate group and 2.6 [2.2–3.1] for prostate bed group. 23 patients from the group of prostate reirradiation had placement of rectal spacers. Median gel thickness at midgland was 6.8 mm, range [3.5–16.9].

Treatment
42 patients were treated: 33 from the prostate group and nine from the prostate bed group. No patients were excluded for dose constraints considerations. The median PTV volume was 33 cm3 (range, 5 to 61) and 6 cm3 (range, 4 ; 14) for prostate group and prostate bed group respectively. The dosimetric plan parameters are detailed in Table 3.

Reponses
Biochemical response was evaluated for the 34 patients of the group who have not received ADT (Table 5). At last follow-up, a biochemical complete response was observed in 26 patients (76%); a biochemical partial response was noticed in three

| Number of patients | Prostate with rectal spacer (n = 23) | Prostate without rectal spacer (n = 10) | Prostate bed (n = 9) | Total (n = 42) |
|-------------------|-------------------------------------|----------------------------------------|---------------------|---------------|
| PTV (median)      |                                     |                                        |                     |               |
| D min             | 31.3 [20 ; 38]                      | 31.3 [22 ; 38]                        | 33 [24 ; 35]        | 31.4 [20 ; 38]|
| D mean            | 29.8 [27 ; 41]                      | 29.8 [27 ; 41]                        | 40.2 [35 ; 42]      | 40.1 [27 ; 42]|
| D max             | 42 [31 ; 45]                        | 42 [31 ; 45]                          | 45 [39 ; 47]        | 45 [31 ; 47]  |
| Volume (cm3)      | 33 [6 ; 61]                         | 31 [5 ; 56]                           | 6 [4 ; 14]          | 29 [4 ; 61]   |
| CTV (median)      |                                     |                                        |                     |               |
| D min             | 34 [4 ; 56]                         | 31.3 [3 ; 51]                        | 31.3 [20 ; 38]      | 34 [3 ; 56]   |
| D max             | 41 [28 ; 43]                        | 38 [28 ; 40]                          | 40.1 [27 ; 42]      | 41 [28 ; 43]  |
| D mean            | 46 [33 ; 48]                        | 42 [31 ; 45]                          | 45 [31 ; 48]        | 45 [31 ; 48]  |
| PTV Cia (median)  | 1.1 [1.21 ; 1.38]                   | 1.2 [1.1 ; 1.48]                      | 1.35 [1.14 ; 1.4]   | 1.17 [1.1 ; 1.4]|
| PTV nCia (median) | 1.1 [1.1 ; 1.4]                     | 1.2 [1.1 ; 1.5]                       | 1.4 [1.9 ; 1.5]     | 1.21 [1.1 ; 1.5]|
| PTV Hia (median)  | 1.2 [1.1 ; 1.3]                     | 1.2 [1.1 ; 1.4]                       | 1.27 [1.23 ; 1.3]   | 1.25 [1.1 ; 1.3]|
| Rectum            |                                     |                                        |                     |               |
| D 20%             | 8 [4.45 ; 24]                       | 12 [6 ; 26.7]                         | 9.9 [2.1 ; 25.7]    | 10 [2.1 ; 26.7]|
| D 50%             | 5 [3.02 ; 36]                       | 8 [6 ; 41.9]                          | 8.6 [0.4 ; 59.3]    | 7 [0.4 ; 59.3] |
| V 27 Gy (cc)      | 0.1 [0 ; 4.5]                       | 1.1 [0.8 ; 8.5]                       | 0.9 [0 ; 19.6]      | 0.7 [0 ; 19.6] |
| D max             | 27.9±13                            | 34.4 [11 ; 39.9]                      | 34.4 [0 ; 41.4]     | 30.2 [0 ; 41.4]|
| Bladder           |                                     |                                        |                     |               |
| D 5 cm3           | 22.5 [11.7 ; 42.8]                  | 23 [11.5 ; 42.8]                      | 15.9 [11.5 ; 20.3]  | 21.2 [11.5 ; 42.8]|
| V 19 Gy (cc)      | 8 [1 ; 19]                         | 8.6 [1.5 ; 20]                        | 4.4 [1.8 ; 9.1]     | 7.1 [1.1 ; 19.6]|
| D max (Gy)        | 38 [2 ; 41]                         | 39 [26.2 ; 41]                        | 36.6 [26.2 ; 44.4]  | 38.2 [25.2 ; 44.4]|

*CI: conformity index, nCI; new conformity index, HI; homogeneity index
patients (9%). Biochemical stabilization was observed in three patients (9%). Two patients (6%) experienced a biochemical failure. All patients were alive at the last follow up. Biochemical failure occurs with a median time of 10 months after radiation therapy. None had a clinical local failure. Six patients had regionally recurrence with pelvic lymph nodes progression confirmed by choline PET/CT, two had a distant failure with bones metastasis and one had both (Table 4). No local recurrence in the prostate or in the prostate bed were observed on follow up images. At 21 months, biochemical complete response was observed in 25 patients (75%): six patients (100%) of prostate bed reirradiation and 19 patients (69%) of the other group.

### Table 4. Treatment outcome (n = 42)

| Number of patients | Prostate with rectal spacer (n = 23) | Prostate without rectal spacer (n = 10) | Prostate bed (n = 9) | Total (n = 42) |
|--------------------|--------------------------------------|----------------------------------------|---------------------|----------------|
| Follow up duration |                                      |                                        |                     |                |
| Median[range]      | 21 [3;31]                            | 18 [4;28]                              | 17 [3;20]           | 21 [3;31]     |
| PFS                |                                      |                                        |                     |                |
| Median [range] (months) | 10 [3 ; 21]               | 9 [4 ; 20]                              | 11 [3 ; 17]         | 11 [3 ; 21]   |
| Site of progression|                                      |                                        |                     |                |
| In field           | 0                                    | 0                                      | 0                   | 0              |
| Out field          | 4                                    | 2                                      | 1                   | 7 (17%)       |
| -Bones             | 1                                    | 0                                      | 0                   | 1 (2%)        |
| -Lymph nodes       | 3                                    | 1                                      | 1                   | 5 (12%)       |
| -Bones and lymph nodes | 1                                    | 0                                      | 1                   | 1 (2%)        |
| Biochemical only   | 0                                    | 0                                      | 1                   | 1 (2%)        |

### Toxicity

15 patients (36%) did not have any acute or late toxicity. No Grade four or five toxicity were observed. The toxicity is reported in Table 5. We recorded 28 acute urinary events: 18 patients (43%), nine patients (21%) and one patients (2%) experienced Grade 1, Grade 2 and Grade 3 urinary toxicity respectively, namely cystitis and/or dysuria. No bladder spasm, hematuria or urinary incontinence were reported. Acute dysuria was significantly correlated with D max of the bladder ($p = 0.037$, CI 99% 0.032; 0.042). We observed 10 (24%) late urinary events: eight Grade 1, one Grade two and one Grade 3 (urinary incontinence). According CTCAE v4, we recorded three (7%) acute Grade one

### Table 5. Toxicities according CTCAE v4 (n = 42)

| Number of patients | Prostate with rectal spacer (n = 23) | Prostate without rectal spacer (n = 10) | Prostate bed (n = 9) | Total (n = 42) |
|--------------------|--------------------------------------|----------------------------------------|---------------------|----------------|
| Acute urinary toxicity |                                      |                                        |                     |                |
| All: Grade 1, Grade 2, Grade 3, > Grade 3 | 14: 10, 3, 1, 0 | 13, 3, 1 | 10: 6, 3, 0, 0 | 3, 1, 0 | 4: 2, 3, 0, 0 | 2, 1, 0 | 28 (64%) | 21 (50%) | 15 (36%) |
| Cystitis Grade 1, Grade 2, Grade 3 | 4, 4 | 0 | 3, 3 | 0 | 0 | 0 | 3 (7%) | 0 | 0 |
| Dysuria Grade 1, Grade 2 | 0, 0 | 0 | 2, 0 | 0 | 1, 0 | 0 | 3 (7%) | 0 | 0 |
| Others | 0, 0 | 0 | 2, 0 | 0 | 1, 0 | 0 | 3 (7%) | 0 | 0 |
| Acute rectal toxicity |                                      |                                        |                     |                |
| Diarrhea Grade 1 > Grade 1 | 0, 0 | 0 | 2, 0 | 0 | 1, 0 | 0 | 3 (7%) | 0 | 0 |
| Others | 0, 0 | 0 | 2, 0 | 0 | 1, 0 | 0 | 3 (7%) | 0 | 0 |
| Late urinary toxicity |                                      |                                        |                     |                |
| Cystitis Grade 1 Grade 2 > Grade 3 | 2, 1, 0 | 3, 0 | 2, 0, 0 | 1, 0 | 1, 1, 0 | 0 | 7 (17%) | 4 (9%) | 1 (2%) |
| Dysuria Grade 1 > Grade 1 | 0 | 0 | 1, 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Urinary incontinence Grade 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Others | 0, 0 | 0 | 2, 0 | 0 | 1, 0 | 0 | 3 (7%) | 0 | 0 |
| Acute rectal toxicity |                                      |                                        |                     |                |
| Diarrhea Grade 1 > Grade 1 | 0, 0 | 0 | 2, 0 | 0 | 1, 0 | 0 | 3 (7%) | 0 | 0 |
| Others | 0, 0 | 0 | 2, 0 | 0 | 1, 0 | 0 | 3 (7%) | 0 | 0 |
| Late rectal toxicity |                                      |                                        |                     |                |
| All | 0, 0 | 0 | 2, 0 | 0 | 1, 0 | 0 | 3 (7%) | 0 | 0 |
rectal toxicity corresponding to diarrhea without any recto-
rhagia or other GI toxicities. No late gastro intestinal events were
reported during the follow up period. We evaluate also the clin-
cal tolerance and the effect of hydrogel rectal spacer on rectal
dosimetry. There were no device-related adverse events, rectal
perforations, serious bleeding, or infections following the place-
fment of rectal spacers. Moreover, rectal doses were statistically
lower with rectal spacer. We found a significant increase in the
volume of rectum receiving high radiation dose without a rectal
spacer as compared with a rectal spacer when treating with SBRT.
The rectal V27 and D max were significantly lower with the rectal
spacer. The median V27 was 0.1 cc with rectal spacer and 1.1 cc
without, p value = 0.022, CI 99% [0.018; 0.026] and median D
max respectively 27.9 Gy and 34.4 Gy, p value = 0.027, CI 99%
[0.023; 0.031]. Functional success (7.5 mm space after hydrogel
placement) and clinical success (≥25% reduction in rectal V27)
was achieved in all of the patients. Acute or late rectal toxicities
were equivalent between patient with and without rectal spacer.

### DISCUSSION

There is no consensus on the most appropriate management of
patient with recurrent prostate cancer after primary radiation.
Several late toxicities about non-radiation-based salvage therapy
have been reported, such as rectal fistula after HIFU. Moreover,
there is no robust evidence in terms of disease control in favor
of cryotherapy or HIFU. The evolution of imaging and treatment
modalities has allowed extremely precise tumor targeting using
extreme hypo fractionation. High fractionation sensitivity is an
intrinsic property of primary prostate cancer. Recent in vivo
and clinical data suggest that prostate cancer may benefit from hypo
fractionation because its α/β ration is lower than that rectum and
other pelvic organs.

Preliminary evidence of reirradiation in other areas has started
to emerge. Therefore, reirradiation has become part of clinical
practice guidelines. SBRT is particularly interesting option
because it makes possible to reduce the safety margin around
the target and thus spare the exposure of the previously irradi-
ated normal tissue. In this context, stereotactic focal reirradia-
tion seems to be particularly attractive. The literature consists of
small-sized series, making it difficult to assess and compare dose
and fractionation. Reirradiation doses were variable ranging
from 15 to 60 in three fractions. The median dose was 30 Gy in
a median of 4.5 fractions.11 Our treatment regimen of 36 Gy in
six fractions is equivalent to the regimen use in other studies in
the same clinical setting.15,16 This regimen seems to be safe and
to obtain good results in terms of efficacy.

In our series, two groups of patients were analyzed: reirradia-
tion on prostate and reirradiation prostatic bed. Our intention
was to report a clinical experience and to evaluate the feasibility
of SBRT in patient with a single recurrence of prostate cancer
in irradiated field. To date, only few studies on stereotactic focal
reirradiation for a local recurrence of prostate cancer have been
published. Zerini and al retrospectively evaluated 32 patients
reirradiated to the prostate or prostatic bed for local recurrence
with a dose of 25 Gy in five fractions.17 They have reported lower
acute urinary toxicity than in our study (19% vs 43% of Grade 1
and 6 vs 21% of Grade 2) with no Grade three or more urinary
toxicity. Moreover, they mention a 2 years tumor control in about
half of the patients. Jereczek-Fossa reported 15 patients reirradi-
ated for local recurrence and four patients reirradiated for anas-
tomosis recurrence at a dose of 30 Gy in five fractions.18 They
find respectively 33% of acute urinary toxicity in prostate group
and 25% in prostrate bed group with a single Grade three urinary
acute and late urinary toxicity. 75% of patients had a complete
biochemical response at the last follow-up which is close to the
results found in this study. Moreover, in the retrospective study
of Janoray and al, 21 patients were treated with 36.25 Gy in five
fractions for local in field recurrence after radical or post pros-
tactomy radiotherapy.15 The 1-year biochemical recurrence free
survival and local control rates were 83.3 and 90% respectively.
At 21 months, we notice similar results with a biochemical free
survival of 72%. Mbeutcha and al reported 18 patients reirra-
diated using focal SBRT with 35 Gy in five fractions.19 After a
median follow up of 14.5 months, 10 out of the 18 patients (56%)
remained free of biochemical recurrence and a single patient
experienced transit Grade four complication. Our study showed
that reirradiation seems to be effective and safe. Our results on
urinary and digestive toxicities are comparable to those obtained
by other salvage therapy. However, further prospective studies
and long-term follow up are needed to confirm the rate of acute

| Number of patients | Prostate (n = 28) | Prostate bed (n = 6) | Total (n = 34) |
|--------------------|------------------|---------------------|--------------|
| Biochemical response at last follow up | | | |
| Complete response | 21 (75%) | 5 (83%) | 26 (76%) |
| Partial response | 3 (11%) | 0 | 3 (9%) |
| Stabilization | 3 (11%) | 0 | 3 (9%) |
| Progressive disease | 1 (4%) | 1 (4%) | 2 (6%) |
| Biochemical response median follow up (21 months) | | | |
| Complete response | 19 (69%) | 6 (100%) | 25 (74%) |
| Partial response | 2 (6%) | 0 | 2 (6%) |
| Stabilization | 2 (6%) | 0 | 2 (6%) |
| Progressive disease | 5 (18%) | 0 | 5 (15%) |

Table 6. Biochemical response (n = 34)
and late toxicity events. On the basis of data on the correlation between late and acute toxicities,\textsuperscript{3,8} we can expect a limited rate of late toxicities. However, a longer follow up is needed to confirm this hypothesis.

The low rectal toxicities could be related to the setup of rectal spacer for more than half of the patients. We found a significant increase in the volume of rectum receiving high dose radiation without a rectal spacer as compared with a rectal spacer. This increase in rectal dose and the implication for a potentially higher risk of rectal toxicity should be considered when deciding to use a rectal spacer. The hydrogel rectal spacer appears to be an effective tool, potentially enabling advanced prostate RT protocols. Prospective clinical studies are needed to identify clinical risk factors to select patients who are expected to benefit most from rectal spacer implantation.

The use of fiducials in modern radiotherapy is recommended especially when considering dose escalation.\textsuperscript{18,19} The use of fiducial markers for prostate/prostate bed daily localization and set up reduces required PTV margins. If fiducial tracking is not possible, we do not recommend reirradiation using spine tracking as it requires larger PTV margins exposing the patient to a risk of significant toxicity and recurrence. The use of rectal spacers and fiducials allow a reduction in acute rectal toxicity\textsuperscript{20} but there is a lack of data on late toxicity and longer-term studies are required. Another approach of external beam salvage irradiation is to do a reirradiation of the whole prostate gland. Two studies\textsuperscript{12,21} report similar results as focal reirradiation in term of biochemical disease-free survival and toxicity. Nevertheless, Zili and al. show after a median follow-up of 94 months, that whole gland reirradiation result in a high rate of severe radiation induced side-effect and poor long term biochemical and local control.\textsuperscript{22} Our approach for reirradiation was slightly different as we used focal reirradiation instead of whole gland treatment. Given the evidence from pathology studies that recurrences are frequently localized at the site of the primary tumor,\textsuperscript{23,24} a focal salvage approach might be a viable treatment option for patients with unifocal prostate cancer recurrence without metastatic disease. Whole gland salvage techniques carry a high risk of toxicity\textsuperscript{22} thus a focal salvage approach might reduce the risk of adverse events while maintaining cancer control. In this study, no local relapse was observed after salvage SBRT. Focal SBRT could be an option to delay the introduction of ADT in some highly selected patients, without exposing patients to high risk of complication.

Low and high-dose rate brachytherapy has also been described as a salvage treatment following radiotherapy. The results of low dose rate salvage brachytherapy have been reported over the last 10 years. Studies have indicated that while tumor control can be achieved in 30 to 50% of patients, toxicity outcomes were increased possibly related to the use of less sophisticated planning techniques.\textsuperscript{25} Available data on salvage reirradiation with high dose rate brachytherapy are sparse and radiation protocol used are heterogeneous. To date, only one Phase II prospective study is available. Yamada et al treated 42 patients with a total dose of 32 Gy in four fractions. Survival without biochemical relapse at 5 years following high-dose-rate brachytherapy was 69% with a median survival time of 36 months; 15% of the patients presented Grade two toxicity, and one patient presented Grade three incontinence.\textsuperscript{26} Moreover, dosimetric comparison between stereotactic body radiotherapy and high dose rate brachytherapy found that EBRT was not able to achieve either the high doses to the prostate or the dose-sparing effect on normal tissues that HDR brachytherapy is able to achieve,\textsuperscript{27} showing the advantages of HDR over external beam techniques. However, because Cyberknife\textsuperscript{®} seems to be the most advanced and suitable technique for prostate EBRT, and an effective and well tolerated tool for the prostate reirradiation, future studies should compare clinical outcomes and toxicity between these modalities.

They are several limitations in this study: One of the main limitation is the heterogeneity of patients. We choose to include both prostate and prostate bed reirradiation because our purpose was to report our experience and the feasibility of this treatment. Otherwise, all patient had prostate biopsies at time of recurrence. Nevertheless, 20% of them have non-pathological features of malignancy with evidence supporting a local recurrence: PSA kinetic, multiparametric pelvis MRI and choline PET/CT findings. Choline PET/CT and MRI have respectively yielded excellent results to confirm focal disease.\textsuperscript{28,29} We choose to hold these patients eligible and we consider that these data are sufficient evidence for salvage reirradiation. Despite very good sensibility of multiparametric MRI and choline PET/CT, prostate biopsy remains the gold standard for diagnosing prostate cancer.\textsuperscript{13} The effective of our study is small and the follow-up is relatively short. Thus, it is complicated to assess the biochemical response and the late toxicity. However, to our knowledge, it is still the longest and largest study published for now and we believe that early results are important in this pathology. The purpose is to report the preliminary result even if prospective studies are warranted.

**CONCLUSIONS**

No clear conclusions can be made from the available data, but early results are promising. Our retrospective study showed that Cyberknife\textsuperscript{®} focal reirradiation is feasible for isolated prostate cancer after radiation therapy fails. It offers excellent results in the field tumor control and low side-effect profile. It is important to note that no severe GU or GI complications were encountered in this cohort despite having had previous high dose of radiation therapy. For highly selected patients, prostate reirradiation using SBRT is a suitable option to treat recurrence after definitive radiation therapy and shows a low toxicity profile. Our data suggest that reirradiation with high dose hypo fractionation may be a rational salvage approach. We also noted an excellent tolerance profile to a patient who received salvage reirradiation despite the high initial dose that patient has received. Prospective study and long term follow up are needed to confirm these findings and identify eligibility criteria for reirradiation therapy.
REFERENCES

1. Kuban DA et al. Long-term multi-institutional analysis of stage T1-T2 prostate cancer treated with radiotherapy in the PSA era. - PubMed - NCBI [Internet]. [cited 7 juill 2017]; Disponible sur:..

2. Neppel-Huber C, Zappa M, Coebergh JW, Rapiti E, Rachta N, Holleczek B, et al. Changes in incidence, survival and mortality of prostate cancer in Europe and the United States in the PSA era: additional diagnoses and avoided deaths. Ann Oncol mai 2012; 23: 1325–34. doi: https://doi.org/10.1093/annonc/mdr414

3. Roach M. The role of PSA in the radiotherapy of prostate cancer. - PubMed - NCBI [Internet]. [cited 7 juill 2017]. Disponible sur: Available from: https://www.ncbi.nlm.nih.gov/pubmed/8669957.

4. Aloni F, De Bari B, Campostrini F, Arcangeli S, Matei DV, Lopex E, et al. Salvage therapy of intraprostatic failure after radical external-beam radiotherapy for prostate cancer: a review. Crit Rev Oncol Hematol 2013; 88: 550–63. doi: https://doi.org/10.1016/j.critrevonc.2013.07.009

5. Agarwal PK, Sadetsky N, Konety BR, Resnick MI, Carroll PR, and the cancer of the prostate strategic urological research endeavor (CaPSURE) Investigators. Treatment failure after primary and salvage therapy for prostate cancer: likelihood, patterns of care, and outcomes. Cancer 2008; 112: 307–14.

6. Prostate Cancer Treatment (PDQ®) — Health Professional Version — National Cancer Institute [Internet]. [cited 7 juill 2017]. Disponible sur: Available from: https://www.cancer.gov/types/prostate/hp/prostate-treatment-pdq.

7. D’Amico AV, Cote K, Loffredo M, Renshaw J, Lee NY. Practical considerations in the re-irradiation of recurrent and second primary head-and-neck cancer: who, why, how, and how much? International Journal of Radiation Oncology*Biology*Physics 2011; 81: 1211–9. doi: https://doi.org/10.1016/j.ijrobp.2011.06.1998

8. Murray LJ, Lilley J, Hawkins MA, Henry AE, Schultz D. Determinants of prostate cancer-Specific survival after radiation therapy in men with clinically localized prostate cancer treated with radiotherapy in the PSA era. Cancer 2014; 18(5–6): 524–34. doi:10.1016/canrad.2014.07.153

9. Chen AM, Phillips TL, Lee NY. Practical considerations in the re-irradiation of recurrent and second primary head-and-neck cancer: who, why, how, and how much? International Journal of Radiation Oncology*Biology*Physics 2011; 81: 1211–9. doi: https://doi.org/10.1016/j.ijrobp.2011.06.1998

10. Pelvic re-irradiation using stereotactic ablative radiotherapy (SABR): A systematic review.Radiotherapy and Oncology.. Available from: https://www.jrсер.org/article/doi:10.1016/j.prro.2015.04.009

11. Kanoun S, Walker P, Vrigneaud J-M, et al. Changes in incidence, survival and mortality of prostate cancer treated with radiotherapy in the PSA era: additional diagnoses and avoided deaths. Ann Oncol mai 2012; 23: 1325–34. doi: https://doi.org/10.1093/annonc/mdr414

12. D’Amico AV, Cote K, Loffredo M, Renshaw J, Lee NY. Practical considerations in the re-irradiation of recurrent and second primary head-and-neck cancer: who, why, how, and how much? International Journal of Radiation Oncology*Biology*Physics 2011; 81: 1211–9. doi: https://doi.org/10.1016/j.ijrobp.2011.06.1998

13. Kanoun S, Walker P, Vrigneaud J-M, Depardon E, Barbier V, Humbert O, et al. F-Choline positron emission tomography/ computed tomography and multiparametric magnetic resonance imaging for the detection of early local recurrence of prostate cancer initially treated by radiation therapy: comparison with systematic 3-dimensional Transperineal mapping biopsy. International Journal of Radiation Oncology*Biology*Physics 2017; 97: 986–94. doi: https://doi.org/10.1016/j.ijrobp.2016.12.025

14. Roach M, Hanks G, Thames H, Schellhammer P, Shipley WU, Sokol GH, et al. Defining biochemical failure following radiation therapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix consensus Conference. International Journal of Radiation Oncology*Biology*Physics 2006; 65: 965–74. doi: https://doi.org/10.1016/j.ijrobp.2006.04.029

15. Janoray G, Reynaud-Bougnoix A, Ruffier-Loubière A, Bernadou G, Pointreau Y, Calais G. Stereotactic body re-irradiation therapy for locally recurrent prostate cancer after external-beam radiation therapy: initial report. Cancer/Radiothérapie 2016; 20: 275–81. doi: https://doi.org/10.1016/j.canrad.2016.03.005

16. Olivier J, Basson L, Puech B, Laceronie T, Villers A, Wallet J, et al. Stereotactic re-irradiation for local recurrence in the prostatic bed after prostatectomy: preliminary results. Front Oncol 2019; 9: 71

17. Zerini D, Jereczek-Fossa BA, Fodor C, Bazzani F, Mauzieri A, Ronchi S, et al. Salvage image-guided intensity modulated or stereotactic body re irradiation of local recurrence of prostate cancer. Br J Radiol 2015; 88: 20150197. doi: https://doi.org/10.1259/bjr/20150197

18. Xie Y, Djaiputra D, King CR, Hossain S, Ma L, Xing L. Intrafractional motion of the prostate during Hypofractionated radiotherapy. International Journal of Radiation Oncology*Biology*Physics 2008; 72: 236–46. doi: https://doi.org/10.1016/j.ijrobp.2008.04.051

19. Lei S, Piel N, Oerern M, Chen V, Ju AW, Dahul KN, et al. Six-Dimensional correction of Intra-Fractional prostate motion with CyberKnife stereotactic body radiation therapy. Front Oncol 2011; 1: 48[Internet]. 2011 [cited 18 juill 2017];1. Disponible sur:. doi: https://doi.org/10.3389/fonc.2011.00048

20. Ng M, Brown E, Williams A, Chao M, Lawrentschuk N, Chee R. Fiducial markers and spacers in prostate radiotherapy: current applications: Fiducial markers and spacers in prostate radiotherapy. BJU Int. mars 2014; 113: 13–20.

21. Fuller DB, Wurzer J, Shirazi R, Bridge SS, Law J, Mardirossian G. High-dose-rate stereotactic body radiation therapy for prostration therapy: comparison with systematic 3-dimensional Transperineal mapping biopsy. International Journal of Radiation Oncology*Biology*Physics 2017; 97: 986–94. doi: https://doi.org/10.1016/j.ijrobp.2016.12.025

22. Zilli T, Benz E, Dipasquale G, Rouzaud M, Mirabelli B. Reirradiation of prostate cancer local failures after previous curative radiation therapy: long-term outcome and tolerance. International Journal of Radiation Oncology*Biology*Physics 2016; 96: 318–22. doi: https://doi.org/10.3389/fonc.2019.00071

23. Cellini N, Morganti AG, Mattucci GC, Valentinii V, Leone M, Luzzi S, et al. Analysis of intraprostatic failures in patients treated with hormonal therapy and radiotherapy: implications for conformal therapy planning. International Journal of Radiation Oncology*Biology*Physics 2002; 53: 595–9. doi: https://doi.org/10.1016/S0360-3016(02)02795-5

24. Pucar D, Hricak H, Shukla-Dave A, Kuroiwa K, Drobnjak M, Eastham J, et al. Clinically significant prostate cancer local recurrence after radiotherapy occurs at the site border.
of primary tumor: magnetic resonance imaging and Step-Section pathology evidence. *International Journal of Radiation Oncology*Biology*Physics* 2007; 69: 62–9. doi: https://doi.org/10.1016/j.ijrobp.2007.03.065

25. Henríquez I, Sancho G, Hervás A, Guix B, Pera J, Gutierrez C, et al. Salvage brachytherapy in prostate local recurrence after radiation therapy: predicting factors for control and toxicity. *Radiat Oncol* 2014; 9: 102. doi: https://doi.org/10.1186/1748-717X-9-102

26. Yamada Y, Kollmeier MA, Pei X, Kan CC, Cohen Gil’ad N, Donat SM, et al. A phase II study of salvage high-dose-rate brachytherapy for the treatment of locally recurrent prostate cancer after definitive external beam radiotherapy. *Brachytherapy* 2014; 13: 111–6. doi: https://doi.org/10.1016/j.brachy.2013.11.005

27. . A comparative dosimetric analysis of virtual stereotactic body radiotherapy to high-dose-rate monotherapy for intermediate-risk prostate cancer - Brachytherapy [Internet]. [cité 1 mai 2018]. Disponible sur: https://www.brachyjournal.com/article/S1538-4721(13)00243-2/pdf.

28. Mitchell CR, Lowe VJ, Rangel LJ, Hung JC, Kwon ED, Karnes RJ. Operational characteristics of (11)c-choline positron emission tomography/computerized tomography for prostate cancer with biochemical recurrence after initial treatment. *J Urol* 2013; 189: 1308–13. doi: https://doi.org/10.1016/j.juro.2012.10.069

29. Abd-Alazeez M, Ramachandran N, Dikaios N, Ahmed HU, Emberton M, Kirkham A, et al. Multiparametric MRI for detection of radiorecurrent prostate cancer: added value of apparent diffusion coefficient maps and dynamic contrast-enhanced images. *Prostate Cancer Prostatic Dis* 2015; 18: 128–36. doi: https://doi.org/10.1038/pcan.2014.55